November 15, 2026·41 min read

NuScale Power (SMR), Financial Analysis

Insights derived from analysing SEC filings. Independent analysis, not a publication of the SEC. Revenue is below $1m a quarter, so margins on revenue run into thousands of %; the margin lines in Figures 1.1 and 2.1 show this scale only, and Table 1.1 and Figure 2.4 give costs and losses in $m.

Revenue Q3 2026
$0.28m
(96.6%) year on year (Q3 2025 $8.24m)
Costs Q3 2026 (revenue less operating income)
$65.1m
(88.1%) year on year (Q3 2025 $546.7m incl. the $495.0m MC1 charge)
Operating margin Q3 2026 (loss)
(23,068%)
Q3 2025 (6,533%); operating loss $64.8m against $538.4m
Key findings
  • Q3 2026 revenue $0.28m against $8.24m, (96.6%) year on year; net loss $45.7m against $532.6m. Q3 2025 carried Fluor FEED Phase 2 work for RoPower, which ended in late 2025, and the $495.0m Milestone Contribution 1 to ENTRA1 in G&A. Costs (revenue less operating income) were $65.1m against $546.7m; excluding that charge Q3 2025 costs were $51.7m, so Q3 2026 costs rose 26.0% (derived).
  • ENTRA1 and TVA: under a non binding agreement of 2 Sep 2025, ENTRA1 and TVA will collaborate to develop plants providing TVA with up to 6 GW of new nuclear generation; the 10-Q states that ENTRA1 entered into a non binding agreement relating to 72 NPMs, which triggered Milestone Contribution 1. NuScale expensed $507.4m for MC1 in 2025 and paid $247.5m in 2025 and $259.9m in 9M 2026. The PMA sets MC1 at 15%, MC2 at 35% (due on a binding PPA) and MC3 at 50% (due on an OEM agreement) of each total Milestone Contribution; applying those shares to the $507.4m gives about $1.18bn for MC2 and $1.69bn for MC3 for the same 72 NPMs, a derivation by this report that the filings do not state. No PMA liability is accrued at 30 Sep 2026.
  • First NPM production: in Oct 2026 NuScale signed a contract with Doosan Enerbility for fabrication of the upper reactor coolant system of the NPM; long lead material work in process, sourced from Doosan, was $69.7m at 30 Sep 2026, and LLM materials purchase commitments of $41.9m fall due in 2027. R&D rose to $18.0m (+62.9%) and labor costs to $32.6m (+47.1%).
  • Cash and investments $1.86bn at 30 Sep 2026, no debt; 89.7m shares were sold in H1 2026 for $1.0bn gross at $11.14 on average, and a new $750m ATM program of 11 Aug 2026 had no sales in Q3 2026. Investment income $19.1m covered 29% of the operating loss. 9M 2026 operating cash use excluding the MC1 payment was $141.5m (derived).
  • Fluor sold its entire stake of 111.4m shares between 13 Feb and 21 Apr 2026, for about $1.83bn on Form 4 prices from $19.05 to $11.63 (derived), and is no longer a related party. A securities class action filed 18 Feb 2026 against NuScale, its CEO and CFO and Fluor, amended on 10 Jul 2026 to add directors, a further individual and ENTRA1, alleges misleading statements on ENTRA1's experience, qualifications and capabilities; NuScale moved to dismiss on 25 Sep 2026.
  • Shares closed at $4.66 on 13 Nov 2026, 80% below the 52 week high of $23.45 (intraday, 14 Nov 2025); market value $2.00bn on Class A plus Class B shares against cash of $1.86bn. This report's model, on its own assumptions of exit EV/sales, revenue and dilution, gives prices in three years of $2.81 (worst), $4.94 (base) and $11.32 (best).

Figures are read from the filings of NuScale Power Corporation (central index key 1822966): the Q3 2026 results release (8-K Item 2.02, Ex 99.1 of 5 Nov 2026) and the Q3 2026 Form 10-Q of the same day, the Forms 10-K for FY2022 to FY2025, the Forms 10-Q for Q1 2025 to Q2 2026, the Forms 8-K with all their exhibits, incl. the results releases for FY2025 to Q2 2026, the ATM sales agreements and the Item 5.07 vote results, the 2026 proxy statement, Fluor's Schedules 13D/A and Forms 4, Schedules 13G and the Forms 4 of officers and directors, and the Forms 10-Q and 10-K of Oklo, NANO Nuclear Energy, BWX Technologies and GE Vernova used in chapters 2 to 4 and 7. NuScale files no separate CFO commentary document, so CFO figures come from the financial update in the releases; earnings call remarks are left out. Share price $4.66 is the regular session close of 13 Nov 2026. Accession numbers appear in the Sources appendix.

1 Revenue & Business Model

  • Storyline: NuScale holds the only NRC approved SMR design, has moved its first NPM into fabrication at Doosan and holds $1.86bn of cash, while revenue fell to near nil after the RoPower engineering work ended and its commercial path runs through ENTRA1 and a TVA program without a binding PPA. Chapters 2 to 4 cover the drivers: ENTRA1 and TVA; RoPower and international markets; supply chain and NPM production.
  • Business (10-K FY2025): NuScale designs the NuScale Power Module, a 77 MWe light water reactor with natural circulation, sold in plants of four, six or twelve modules (up to 924 MWe). Planned revenue: NPM and equipment sales, technology licences, and services from about five years before a plant's commercial operation date.
  • Regulatory position: the NRC approved the 50 MWe 12 module design in Sep 2020 and the uprated 77 MWe 6 module standard design approval in May 2025; the 10-K states that no other SMR or advanced reactor company has applied to the NRC for an SDA.
  • Revenue to date is engineering and licensing work: FY2021 $2.9m, FY2023 $22.8m, FY2024 $37.0m (incl. the RoPower technology licence), FY2025 $31.5m and 9M 2026 $0.9m. Fluor supplied 76% of 9M 2025 revenue. In Q3 2026, $0.26m came from Energy Exploration Center simulators and $0.02m from plant and NPM services.
  • Structure: NuScale Corp consolidates NuScale LLC. Class B shares (one vote, no economics) pair with NuScale LLC units exchangeable for Class A; they were 4.5% of combined interests at 30 Sep 2026 against 43.8% a year earlier, after Fluor's exchange of 110.9m units on 7 Nov 2025.
  • Reporting and workforce: one segment; the CEO, CCO and CFO review consolidated net loss. 428 full time employees at 31 Dec 2025; over $1.8bn invested in the technology since 2007, incl. $578.3m from the DOE; 513 patents granted.
Figure 1.1 Revenue ($m) and operating margin (thousands of %), FY2021 to TTM Q3 2026
Table 1.1 Quarterly income statement, cash flow and cash in $m, Q1 2025 to Q3 2026
Line ($m unless stated)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue13.388.058.241.810.570.080.28
of which from Fluor (related party)7.277.437.871.350.000.000.00
Cost of sales6.376.275.531.870.540.230.15
Research and development9.111.811.113.512.818.418.0
General and administrative23.322.5519.244.824.826.927.9
Other expenses9.910.510.914.319.918.519.0
Operating loss(35.3)(43.1)(538.4)(72.7)(57.5)(64.0)(64.8)
Investment income5.25.55.88.910.813.919.1
Net loss incl. noncontrolling interests(30.4)(37.6)(532.6)(63.8)(46.7)(50.1)(45.7)
Net loss to Class A stockholders(14.0)(17.6)(273.3)(50.8)(44.0)(47.5)(43.7)
Loss per Class A share ($)(0.11)(0.13)(1.85)n/a(0.14)(0.13)(0.11)
Operating cash flow(22.8)(33.3)(199.8)(203.7)(314.7)(58.2)(28.6)
Capital expenditure(0.07)0.00(0.07)(0.37)(1.52)(0.43)(0.09)
Equity raised, net99.80.0462.6737.437.3947.20.0
Cash and investments, quarter end521.4489.9753.81,287.21,008.81,893.01,864.1
Long lead material work in process, quarter end45.064.363.363.865.168.669.7
Q4 2025 equals FY2025 less 9M 2025; Q4 2025 loss per share is not derivable from year to date figures. Cash flow quarters derived from year to date figures. G&A includes Milestone Contribution 1: $495.0m in Q3 2025 and the balance of the $507.4m in Q4 2025. Cash and investments include short and long term investments.

2 ENTRA1 and TVA: Up to 6 GW, a $507m First Milestone and No Binding PPA Yet

  • TVA program: on 2 Sep 2025 TVA and ENTRA1 signed a non binding agreement to develop plants providing TVA with up to 6 GW of new nuclear generation; ENTRA1's stated strategy is to use NuScale SMR equipment. The 10-K states that ENTRA1 is negotiating with TVA to deploy up to six 12 module plants in TVA's seven state region.
  • Milestone Contribution 1: the 10-Q states the MC1 criteria were met in 2025 as ENTRA1 entered into a non binding agreement relating to 72 NPMs; NuScale expensed $507.4m in 2025 and paid $247.5m in 2025 and $259.9m in 9M 2026. The PMA sets MC1 at 15% of each total Milestone Contribution. This report's derivation, which the filings do not state, scales the $507.4m to about $3.38bn in total, $1.18bn of it due on a binding PPA and $1.69bn on an OEM agreement.
  • Terms (10-Q Note 9): NuScale is the key supplier for ENTRA1 Energy Projects to 31 Dec 2045, while ENTRA1 keeps sole discretion to buy from NuScale; contributions are creditable against future projects if a project is not completed; the PMA caps the NPM sale price.
  • Status at 5 Nov 2026: the Q3 2026 release states that NuScale continues to support ENTRA1 in its dialogue with TVA; the 10-Q states that the next phase depends on one or more PPAs between ENTRA1 and TVA. ENTRA1 also pursues hyperscaler, technology, industrial and micro grid customers.

How the US nuclear market is changing

  • US executive order of May 2025: 400 GW of US nuclear capacity by 2050 from about 100 GW in 2024 (10-K FY2025).
  • On 2 Sep 2025 TVA and ENTRA1 entered into a non binding collaborative agreement to develop plants providing TVA with up to 6 GW of new nuclear generation (10-K FY2025); the next phase depends on one or more PPAs between ENTRA1 and TVA (10-Q Q3 2026).
  • US demand is driven by data centers, AI, cloud computing and digital transformation (10-Q Q3 2026 outlook).
  • Oklo holds a 2024 letter of intent with a data center operator for 20 year power supply with a 36 month right of first refusal (Oklo 10-Q Q3 2026).
  • NANO Nuclear (10-Q, Jun 2026 quarter): the University of Illinois construction permit application for a KRONOS micro reactor was accepted for NRC review on 18 May 2026.
Figure 2.1 PMA milestone contributions for 72 NPMs against cash
Figure 2.2 Market value against cash, advanced reactor developers
Table 2.1 Advanced reactor developers compared, latest filed quarter
CompanyLinePeriodValueGrowth (%)Margin (%)Detail
NuScale PowerRevenueQ3 2026$0.28m(96.6)n/aoperating loss $64.8m; cash and investments $1.86bn
OkloRevenueQ3 2026$1.86mn/an/aoperating loss $71.0m; cash and debt securities $3.13bn
NANO Nuclear EnergyRevenueJun 2026 quarter$0.21mn/an/aoperating loss $15.8m; KRONOS construction permit application accepted 18 May 2026
NANO Nuclear's fiscal year ends 30 Sep. Oklo and NANO Nuclear reported first revenue in 2026, so growth is n/a.

3 RoPower and International: Romania Approved the Doicesti Investment, FEED Revenue Ended

  • RoPower: a joint venture of S.N. Nuclearelectrica and Nova Power & Gas plans a plant on NuScale's 6 unit 77 MWe design at the Doicesti Power Station site in Romania (10-K). NuScale licensed technology to RoPower in Jul 2024 and worked as subcontractor to Fluor on FEED Phase 2, completed in late 2025.
  • Next phase: the Romanian Government approved the investment decision on 12 Feb 2026; RoPower may advance licensing and geotechnical work and negotiate a pre EPC contract and long lead items, but the 10-Q expects no pre EPC contract before RoPower secures financing.
  • Revenue effect: Fluor supplied $7.9m, or 96%, of Q3 2025 revenue and none in 2026; 9M 2026 revenue was $0.9m against $29.7m, of which Energy Exploration Center simulators $0.59m. E2 Centers operate in 11 facilities in the US, Europe, Asia and Africa (10-K).
  • Other markets: with ENTRA1, NuScale develops interest from foreign governments; the 10-Q cites a forecast that Asia accounts for nearly 60% of global growth in electricity use through 2050. NuScale's design is approved only in the US, and approvals are needed country by country (10-K).

How international and utility demand is changing

  • Romanian Government approved the investment decision for the RoPower Doicesti SMR plant on 12 Feb 2026; RoPower must secure financing before a pre EPC contract (10-Q Q3 2026).
  • Asia is forecast to account for nearly 60% of global growth in electricity use through 2050 (10-Q Q3 2026).
  • Commercial SMRs operate in China and Russia; NuScale's is the first and only SMR design to receive an NRC SDA (10-K FY2025).
  • GE Vernova (10-Q Q3 2026): Power segment covers gas, nuclear and hydro equipment; company RPO $196.7bn at 30 Sep 2026.
Figure 3.1 Quarterly revenue and the Fluor related party share
Figure 3.2 Revenue by year
Table 3.1 Revenue base against a utility equipment supplier
CompanyLinePeriodValueGrowth (%)Margin (%)Detail
NuScale PowerRevenue9M 2026$0.92m(96.9)n/aRoPower FEED Phase 2 ended late 2025; E2 Centers $0.59m
GE VernovaRevenueQ3 2026$12.64bn26.811.0Power segment covers gas, nuclear and hydro; RPO $196.7bn
GE Vernova margin is GAAP operating margin for Q3 2026 ($1.39bn on $12.64bn).

4 Supply Chain and First NPM Production: Doosan Upper Reactor Contract and $69.7m of Long Lead Material

  • Doosan: long lead material work in process, raw materials from Doosan for heavy forgings, steam generator tubes and weld material, stood at $69.7m at 30 Sep 2026 against $63.3m a year earlier; LLM materials purchase commitments of $41.9m fall due in 2027. In Oct 2026 NuScale executed a contract with Doosan for fabrication of the upper reactor coolant system, which the release calls the most complex and foundational component of the NPM.
  • Other suppliers: Paragon contracts of $25.8m (Jun 2026) for the Highly Integrated Protection System; MillenniTEK fabricated reactor safety components; Framatome expanded its fuel partnership (Q1 2026 release); the Q2 2026 release cites more than 60 supply chain partners and over 30 agreements.
  • Spending: R&D $18.0m in Q3 2026 (+62.9%), mainly design maturity of NPM components; 9M 2026 R&D $49.2m against $32.0m. Capex stays small at $2.0m in 9M 2026.
  • Payment terms (10-K): NuScale expects payments for NPM fabrication to coincide with material orders and the start of manufacturing, so that it carries no working capital for work in process or finished modules.

How the nuclear supply chain is changing

  • BWXT, a supplier of naval reactors, nuclear components and fuel, reported RPO of $8.56bn at 30 Sep 2026 (BWXT 10-Q).
  • NuScale's FY2025 10-K adds a risk factor that its supply base is constrained and competing orders may take manufacturing slots.
  • Oklo (10-Q Q3 2026): capex of $280.9m in 9M 2026 as it builds its first powerhouse and fuel facilities, against NuScale's $2.0m.
Figure 4.1 Long lead material and R&D spending
Figure 4.2 Cash obligations and commitments by year
Table 4.1 Spending and order books in the nuclear supply chain
CompanyLinePeriodValueGrowth (%)Margin (%)Detail
NuScale PowerR&D expenseQ3 2026$18.0m62.9n/aLLM work in process $69.7m; commitments $169.8m
BWX TechnologiesRevenueQ3 2026$953.0m10.013.9RPO $8.56bn; Commercial Operations makes steam generators and reactor components
BWXT margin is GAAP operating margin for Q3 2026 ($132.1m on $953.0m).

5 Financial Analysis & Ratios

  • Operating loss TTM $259.1m on revenue of $2.7m; FY2025 operating loss $689.6m incl. the $507.4m MC1 charge, against $138.7m in FY2024 and $275.6m in FY2023.
  • Net loss TTM $206.3m incl. noncontrolling interests after investment income of $52.8m; loss to Class A stockholders $186.0m. FY2024 included a $223.0m charge for the change in fair value of warrants.
  • Free cash flow TTM ($607.5m): operating cash flow ($605.1m), incl. MC1 payments of $247.5m in Q4 2025 and $259.9m in Q1 2026, and capex of $2.4m.
  • Balance sheet at 30 Sep 2026: cash $513.4m, short term investments $420.0m, long term investments $930.7m; no debt; total liabilities $45.6m; equity $1.97bn; accumulated deficit $868.1m.
  • Capital returns: no dividends and no buybacks in any year shown; the 10-K adds a risk factor that no cash dividends are expected.
Table 5.1 Income statement, cash flow and balance sheet summary ($m unless stated)
Line itemFY2021FY2022FY2023FY2024FY2025TTM Q3 2026
Revenue2.911.822.837.031.52.7
Gross profit1.14.53.832.111.4(0.1)
Research and development93.1123.4156.146.845.562.8
Selling, general and administrative45.263.165.475.9609.8124.4
Operating income(174.3)(230.0)(275.6)(138.7)(689.6)(259.1)
Net income(102.5)(141.6)(180.1)(348.4)(664.5)(206.3)
Diluted EPS ($)n/a(0.51)(0.80)(1.47)(2.17)n/a
Operating cash flow(99.2)(148.6)(183.3)(108.7)(459.6)(605.1)
Capital expenditure(2.0)(2.3)(1.7)0.0(0.5)(2.4)
Free cash flow(101.1)(150.9)(185.0)(108.7)(460.1)(607.5)
Stock based compensation6.49.316.213.619.222.7
Cash and investments77.1267.7120.3441.61,287.21,864.1
Total debt14.00.00.00.00.00.0
Total equity66.3277.1129.3453.11,113.61,974.4
Values in $m. Net income is the consolidated net loss incl. noncontrolling interests. FY2021 is NuScale Power LLC before the May 2022 merger. Cash and investments include short and long term investments. TTM equals Q4 2025 plus 9M 2026.
Figure 5.1 Quarterly revenue and margins
Table 5.2 What changed, Q3 2026 against Q3 2025
MetricQ3 2025Q3 2026Change
Revenue ($m)8.20.3(96.6%)
Gross profit ($m)2.70.1(95.1%)
Operating income ($m)(538.4)(64.8)88.0%
Net income ($m)(532.6)(45.7)91.4%
Diluted EPS ($)(1.85)(0.11)94.1%
Operating cash flow ($m)(199.8)(28.6)85.7%
Free cash flow ($m)(199.9)(28.7)85.7%
Operating margin (%)(6,532.9)(23,067.6)(16,534.7 pts)
Net margin (%)(6,462.6)(16,266.5)(9,804.0 pts)
Table 5.3 Ratio analysis
RatioFY2021FY2022FY2023FY2024FY2025TTM Q3 2026
Growth and margins
Revenue growth (%)n/a312.493.262.4(15.0)n/a
Gross margin (%)38.238.016.986.736.3(2.2)
Liquidity and leverage
Current ratio (x)1.787.381.775.254.3024.40
Net cash ($bn)0.10.30.10.41.31.9
Revenue is below the cost of a single quarter of operations, so margins on revenue and returns ratios are left out. Net cash equals cash and investments; NuScale has no debt.
Figure 5.2 Operating cash flow, capital expenditure and free cash flow
Table 5.4 Valuation snapshot at $4.66 per share, close of 13 Nov 2026
MeasureValue
Market cap ($bn)2.0
Enterprise value ($bn)0.1
FCF yield (%)(30.3)
Price/Book (x)1.0

Cost structure and profitability

  • Costs (revenue less operating income) $65.1m in Q3 2026 against $546.7m; excluding the $495.0m MC1 charge, Q3 2025 costs were $51.7m and Q3 2026 costs rose 26.0% (derived).
  • R&D $18.0m (+62.9%), G&A $27.9m and other expenses $19.0m (+75.0%); labor costs across all lines $32.6m against $22.2m, $95.5m in 9M 2026. Stock based compensation $18.1m in 9M 2026 against $14.5m.
  • Gross margin: cost of sales $0.15m against revenue of $0.28m; Q2 2026 gross margin was negative at ($0.15m).
  • Investment income $19.1m in Q3 2026 and $43.9m in 9M 2026, against $16.4m in 9M 2025, on cash and investments of $1.86bn.
Figure 5.4 Costs by line excluding Milestone Contribution 1
Table 5.5 What changed, Q3 2026 against Q3 2025 ($m)
Line ($m)Q3 2025Q3 2026Change
Revenue8.240.28(96.6%)
Cost of sales5.530.15(97.3%)
Research and development11.118.0+62.9%
General and administrative519.227.9(94.6%)
Other expenses10.919.0+75.0%
Operating loss(538.4)(64.8)(88.0%)
Investment income5.7619.1+231.7%
Net loss incl. noncontrolling interests(532.6)(45.7)(91.4%)
Net loss to Class A stockholders(273.3)(43.7)(84.0%)
G&A excluding Milestone Contribution 1 (derived)24.227.9+15.3%
Costs excluding Milestone Contribution 1 (derived)51.765.1+26.0%
Labor costs (all expense lines)22.232.6+47.1%
Changes in losses are shown as the change in size. Derived lines remove the $495.0m MC1 charge recognized in Q3 2025 (MD&A).

Funding: cash, equity raises and share count

  • Cash and investments rose from $1.29bn at 31 Dec 2025 to $1.86bn at 30 Sep 2026 after $984.5m of net ATM proceeds and operating cash use of $401.4m; $930.7m sits in investments maturing after twelve months.
  • Equity raised: $577.6m in 9M 2025 at $33.68 on average, $750.0m in Q4 2025 (39.3m shares) and $1.0bn in H1 2026 at $11.14 (89.7m shares); the 11 Aug 2026 program for $750m was unused at 30 Sep 2026.
  • Share count: combined Class A and Class B interests rose from 277.1m at 31 Dec 2024 to 429.9m at 30 Sep 2026 (+55.1%); Class A alone from 122.8m to 410.5m, as Class B units were exchanged.
Figure 5.5 Cash and investments, equity raised and operating cash flow
Figure 5.6 Shares outstanding by class
Table 5.6 Equity raised under ATM programs
PeriodProgramShares (m)Gross proceeds ($m)Average price ($)
9M 20252025 ATM ($500m, Aug 2025) and a prior program17.8577.633.68
Q4 2025ATM program of 7 Nov 202539.3750.0n/a
9M 20262026 ATM ($1.0bn, Feb 2026), completed Jun 202689.71,000.011.14
Q3 2026ATM of 11 Aug 2026 ($750m)0.00.0n/a
10-Q Q3 2025 and Q3 2026, FY2025 results release. Q4 2025 average price is not stated in the filings.

6 MD&A & Management Commentary

Q3 2026 results release and 10-Q MD&A

  • Revenue and cost of sales (MD&A): revenue fell $8.0m and cost of sales $5.4m, as Fluor FEED Phase 2 services for RoPower ended in late 2025 with no comparable 2026 activity.
  • Operating costs: R&D $18.0m, +$7.0m, of which $6.7m for technology readiness and design maturity of NPM components; G&A $27.9m, down $491.3m on the 2025 MC1 charge, with higher pay, ERP and insurance costs; other expenses $19.0m, +$8.1m, as fewer engineers worked on commercial projects billed to cost of sales.
  • Investment income $19.1m against $5.8m (+$13.4m) from larger cash balances and investments. Net loss to Class A stockholders $43.7m, or $0.11 a share, against $273.3m, or $1.85.
  • 9M 2026: revenue $0.9m against $29.7m; R&D +$17.3m; G&A down $485.4m; other expenses +$26.2m; operating cash use $401.4m incl. the $259.9m ENTRA1 payment, lower customer collections and prepayments for long lead material.
  • Liquidity (10-Q): management states that cash and investments, with access to capital markets, cover cash needs for the next 12 months and beyond. Commitments total $169.8m, incl. $43.5m under the ENTRA1 sales and marketing agreement ($34.8m a year) and $25.8m of Paragon HIPS contracts.
Table 6.1 Outlook statements as filed; NuScale gives no financial guidance
ItemOutlookSource
Financial guidancenone given for revenue, costs or cash use in any 2026 release8-K Ex 99.1, 26 Feb, 7 May, 5 Aug and 5 Nov 2026
TVA programnext phase of the ENTRA1 and TVA collaboration depends on one or more PPAs between ENTRA1 and TVA; NuScale is positioning to support it10-Q Q3 2026 MD&A
RoPowerno pre EPC contract expected until RoPower secures financing; NuScale expects to recommence work once one is signed10-Q Q3 2026 MD&A
Liquiditysufficient for the next 12 months and beyond, with continued access to capital markets10-Q Q3 2026 MD&A
PMA paymentsMC2 on a binding PPA, MC3 on an OEM agreement; criteria not met at 30 Sep 202610-Q Q3 2026 Note 9
2026 focus (Feb 2026)commercialization and full readiness to manufacture the first NPM8-K Ex 99.1, 26 Feb 2026

Management and CFO commentary

  • NuScale files no separate CFO commentary document; the points below come from the CEO statements and the financial update in the releases filed as 8-K Ex 99.1.
  • Q3 2026 release (5 Nov 2026), CEO John Hopkins: the quarter moved NuScale from development to physical production of its first commercial NPM; the Doosan contract moves the NRC approved design into build; liquidity supports investment toward full scale production. Nuclear specific AI tools from Nuclearn and NPX were deployed in engineering.
  • Q3 2026 financial update: revenue $8.0m lower and cost of sales $5.4m lower on the end of FEED Phase 2; R&D +$7.0m; G&A $491.3m lower; other expenses +$8.1m; investment income +$13.4m.
  • Q2 2026 release (5 Aug 2026): ENTRA1 continues talks with TVA toward a definitive PPA; NuScale works with Nuclearelectrica and RoPower on conditions attached to the shareholder vote; Paragon awarded the HIPS final design; liquidity $1.9bn.
  • Q1 2026 release (7 May 2026): ENTRA1 and TVA progress planning for up to 6 GW of NuScale capacity; Nuclearelectrica shareholders approved the next RoPower phase; liquidity $1.0bn.
  • FY2025 release (26 Feb 2026): 2026 focus on commercialization and readiness to manufacture the first NPM; 39.3m shares sold in Q4 2025 for $750.0m gross.
Table 6.2 Management statements in their own words
SpeakerDate and sourceStatement
John Hopkins, CEO5 Nov 2026, 8-K Ex 99.1“physical production of our first commercial NuScale Power Module”
John Hopkins, CEO5 Aug 2026, 8-K Ex 99.1“that work is now substantially complete”
John Hopkins, CEO26 Feb 2026, 8-K Ex 99.1“ensuring full readiness for the manufacturing of our first NPM”
Table 6.3 Key disclosures in the Forms 10-Q and 10-K
ItemDisclosure
10-Q Q3 2026, Note 9 (PMA)Milestone Contribution 1 for 72 NPMs cost $507.4m: $247.5m settled in 2025 and $259.9m in 9M 2026; no accrued PMA liability at 30 Sep 2026.
10-Q Q3 2026, liquidityCash $513.4m, short term investments $420.0m, long term investments $930.7m, no debt; 89.7m shares sold in 9M 2026 for $1.0bn gross at $11.14 on average.
10-Q Q3 2026, legalTruedson class action (filed 18 Feb 2026, amended 10 Jul 2026) on statements about ENTRA1; motion to dismiss filed 25 Sep 2026; two derivative suits (24 Mar and 28 Oct 2026).
10-Q Q3 2026, commitmentsCash commitments $169.8m, incl. $41.9m of LLM purchases due 2027, $43.5m under the ENTRA1 sales and marketing agreement and $25.8m of Paragon contracts (Jun 2026).
10-Q Q3 2026, related partyFluor divested all Class A shares and is no longer a related party; it supplied 96% of Q3 2025 revenue ($7.9m).
10-K FY2025, Item 1Over $1.8bn invested in NuScale technology since 2007, incl. $578.3m from the DOE; 513 patents granted and 268 pending; 428 full time employees at 31 Dec 2025.
10-K FY2025, Item 1NRC approved the 50 MWe 12 module design in Sep 2020 and the 77 MWe 6 module design (SDA) in May 2025; long lead items ordered from Doosan for the first twelve NPM upper reactor vessels.
10-K FY2025, Item 1ENTRA1 holds exclusive worldwide commercialization rights under the Strategic Alliance Agreement effective 7 May 2025 and negotiates with TVA on up to six 12 module plants.
10-K FY2025, Item 1ANo binding contract to deliver NPMs exists; initial deployment depends on RoPower and Fluor EPC, or an ENTRA1 PPA with a third party and an OEM agreement with NuScale.

7 Peer Valuation & Sector Summary

  • Sector: nuclear reactor developers and nuclear equipment makers. Peers filing with the SEC: Oklo (Aurora fast reactors, 15 to 75 MWe) and NANO Nuclear Energy (KRONOS micro reactor) as pre revenue developers; BWX Technologies (naval reactors, fuel and components) and GE Vernova (gas, nuclear and hydro equipment in its Power segment) as profitable suppliers.
  • Revenue latest quarter: NuScale $0.28m, Oklo $1.86m (Q3 2026, first revenue in 2026), NANO Nuclear $0.21m (Jun 2026 quarter); BWXT $953m (+10.0%) and GE Vernova $12.64bn (+26.8%).
  • Operating loss TTM (Q3 2026; NANO Nuclear to the Jun 2026 quarter): NuScale $259m, Oklo $252m, NANO Nuclear $52m; free cash flow TTM NuScale ($608m), Oklo ($452m), NANO Nuclear ($38m).
  • Valuation against cash (cash at 30 Sep 2026, NANO Nuclear 30 Jun 2026; closes of 13 Nov 2026): market value NuScale $2.00bn against $1.86bn of cash, Oklo $4.67bn against $3.13bn, NANO Nuclear $597m against $580m; BWXT trades at 30.1x TTM Q3 2026 earnings and GE Vernova at 4.5x TTM Q3 2026 EV/sales.
Table 7.1 Peer comparison, latest reported trailing twelve months
CompanyRevenue TTM ($bn)Revenue growth (%)Gross margin (%)Operating margin (%)Net margin (%)FCF margin (%)ROE (%)Net cash ($bn)Market value ($bn)EV/Sales (x)P/E TTM (x)
SMR0.0n/an/an/an/an/an/a1.92n/an/a
OKLO0.0n/an/an/an/an/an/a3.15n/an/a
BWXT3.610.022.612.410.410.328.3(1.5)113.530.1
GEV44.026.821.76.423.5n/a91.913.92134.520.5
NNE0.0n/an/an/an/an/an/a0.61n/an/a
SMR and OKLO TTM to Q3 2026 from their Forms 10-K FY2025 and 10-Q Q3 2026; NNE fiscal year ends 30 Sep, TTM to the Jun 2026 quarter; BWXT and GEV TTM to Q3 2026, growth Q3 2026 year on year. GEV net income includes non operating gains. Revenue below $5m shows as 0.0 in $bn; Table 7.2 gives $m. Prices are closes of 13 Nov 2026.
Figure 7.1 Revenue growth versus operating margin, peer set
Table 7.2 Nuclear peers in $m
CompanyPeriodRevenue ($m)Operating income ($m)Free cash flow ($m)Cash and investments ($m)Market value ($bn)
NuScale Power (SMR)TTM Q3 20262.7(259)(608)1,8642.00
Oklo (OKLO)TTM Q3 20263.1(252)(452)3,1314.67
NANO Nuclear Energy (NNE)TTM Jun 2026 quarter0.2(52)(38)5800.60
BWX Technologies (BWXT)TTM Q3 20263,600.744537256911.27
GE Vernova (GEV)TTM Q3 202644,040.02,828n/a16,764212.57
Gives the $m figures that round to 0.0 in Table 7.1. Oklo cash incl. marketable debt securities; NANO Nuclear cash plus short term investments at 30 Jun 2026; GE Vernova cash incl. restricted cash, FCF not computed; BWXT debt $2.02bn. Market values on cover page share counts and 13 Nov 2026 closes.

8 Material Events & Contracts

  • 11 Forms 8-K from 17 Nov 2025 to 5 Nov 2026: four results releases, two call announcements, two ATM sales agreements, the special meeting that doubled authorized Class A shares, the annual meeting and an officer appointment with a bylaw amendment.
  • Material contracts: the Partnership Milestones Agreement and Strategic Alliance Agreement with ENTRA1, the ENTRA1 sales and marketing agreement, ATM sales agreements, the Doosan contracts for long lead material and the upper reactor coolant system, the Paragon HIPS contracts and the Tax Receivable Agreement as amended with Fluor.
Table 8.1 11 Forms 8-K filed from 17 Nov 2025 to 5 Nov 2026
DateItemsEvent
17 Nov 20255.02, 5.03, 8.01David Tonnel appointed Chief Accounting Officer from 22 Nov 2025; bylaws amended to name the Chief Accounting Officer as an officer; deferred compensation plan for non employee directors adopted (Ex 3.1, Ex 10.1).
17 Dec 20255.03, 5.07Special meeting of 16 Dec 2025 approved raising authorized Class A shares from 332,000,000 to 662,000,000: 184.5m for, 28.0m against, 0.6m abstain; certificate of amendment filed (Ex 3.1).
27 Jan 20267.01Ex 99.1 announced the Q4 and FY2025 results call for 26 Feb 2026.
26 Feb 20262.02FY2025 results (Ex 99.1): revenue $31.5m against $37.0m; G&A $609.8m incl. Milestone Contribution 1 of $507.4m to ENTRA1; net loss $664.5m; cash and investments $1.3bn; 39.3m shares sold under the ATM program in Q4 2025 for $750.0m gross.
26 Feb 20261.01, 1.02New ATM sales agreement for up to $1.0bn of Class A stock with UBS, B. Riley, Canaccord and Tuohy Brothers, commission up to 2%; the 7 Nov 2025 ATM agreement terminated (Ex 1.1, 5.1, 23.1).
8 Apr 20267.01Ex 99.1 announced the Q1 2026 results call for 7 May 2026.
7 May 20262.02Q1 2026 results (Ex 99.1): revenue $0.6m against $13.4m; net loss $46.7m; operating cash use $314.7m incl. the $259.9m ENTRA1 payment; liquidity $1.0bn; Nuclearelectrica shareholders approved the next RoPower phase; Framatome fuel partnership expanded.
2 Jun 20265.07Annual meeting of 29 May 2026: nine directors elected (Kimberly Warnica 78.9m for, 36.9m withheld; Stuart Harshaw 83.7m for, 32.1m withheld); say on pay 110.8m for, 4.2m against; Ernst & Young ratified.
5 Aug 20262.02Q2 2026 results (Ex 99.1): revenue $0.1m against $8.1m; net loss $50.1m; liquidity $1.9bn after the $1.0bn ATM program completed in Jun 2026; Paragon awarded the HIPS final design contract.
11 Aug 20261.01New ATM sales agreement for up to $750m of Class A stock with UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers, commission up to 2% (Ex 1.1, 5.1); no sales in Q3 2026 (10-Q).
5 Nov 20262.02Q3 2026 results (Ex 99.1): revenue $0.3m against $8.2m; G&A $27.9m against $519.2m; net loss $45.7m; cash and investments $1.9bn; Doosan contract for the upper reactor coolant system of the first NPM.
Table 8.2 Material contracts and financing arrangements
ContractTerms
Partnership Milestones Agreement with ENTRA1 (27 Aug 2025)NuScale named key supplier for ENTRA1 Energy Projects to 31 Dec 2045 (renews for 20 years); contributions per NPM in three tranches of 15%, 35% and 50%; MC1 $507.4m for 72 NPMs paid; negotiated maximum NPM sale price; NuScale Corp guarantees NuScale LLC's obligations.
Strategic Alliance Agreement with ENTRA1 (amended and restated, 7 May 2025)ENTRA1 holds exclusive worldwide rights to commercialize NuScale products and plants; NuScale needs ENTRA1 consent to pursue opportunities without it (10-K and 10-Q).
Sales and marketing agreement with ENTRA1 (2023, amended 1 Jan 2025)$34.8m a year; renews annually unless terminated on six months' notice; $8.7m due in Q4 2026 and $34.8m in 2027.
ATM sales agreement of 26 Feb 2026up to $1.0bn; completed Jun 2026 with 89.7m shares at $11.14 on average; commission up to 2%.
ATM sales agreement of 11 Aug 2026up to $750m via UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers; no sales in Q3 2026.
Doosan Enerbility contractsorders for long lead items for the first twelve NPM upper reactor vessels (10-K); LLM sourced from Doosan $69.7m in work in process at 30 Sep 2026; LLM materials purchase commitments $41.9m due 2027; Oct 2026 contract for fabrication of the upper reactor coolant system.
Paragon Energy Solutions (Jun 2026)supply chain readiness and design contracts totaling $25.8m for the Highly Integrated Protection System.
Tax Receivable Agreement amendment with Fluor (6 Nov 2025)payments due to Fluor under the 2022 TRA cut by 50%, alongside Fluor's exchange of 110,936,472 units into Class A shares (Schedule 13D/A no. 6).

9 Ownership, Voting Power & Annual Meeting

  • Two voting classes, one vote per share: Class A 410.6m and Class B 19.3m at 30 Oct 2026. Van Eck holds 6.8% of Class A, BlackRock 6.5% and Vanguard Capital Management 5.25%; Japan NuScale Innovation holds 19.3m Class B shares; directors and executive officers 1.28% (2026 proxy).
  • Fluor, the former largest holder, exited: it exchanged its units in Nov 2025, sold 71.0m shares to Goldman Sachs at $19.0498 on 13 Feb 2026 and the remaining 40.4m in Feb and Apr 2026, for about $1.83bn in total (derived from Forms 4).
  • Annual meeting of 29 May 2026: nine directors elected; Kimberly Warnica received 68.1% and Stuart Harshaw 72.3% of votes cast, against 98.7% for CEO John Hopkins; say on pay 96.3%. A special meeting on 16 Dec 2025 raised authorized Class A shares from 332m to 662m (87.0% of votes cast for).
  • Insiders, 14 Nov 2025 to 15 Nov 2026: no open market purchases; officers and directors sold 392,081 shares for $4.82m, of which $2.06m under Rule 10b5‑1 plans ($1.44m CFO, $0.62m COO). The CEO and CCO adopted Rule 10b5‑1 plans on 11 Aug 2026 (10-Q). CEO total pay in the FY2025 summary compensation table: $4.08m.
Table 9.1 Annual meeting vote results, 29 May 2026
ProposalFor (m votes)Against (m votes)Abstain (m votes)For as % of votes castResult
Elect John L. Hopkins (CEO)114.41.5n/a98.7Elected
Elect Alan L. Boeckmann (chair)107.68.3n/a92.9Elected
Elect Stuart Harshaw83.732.1n/a72.3Elected
Elect Kimberly O. Warnica78.936.9n/a68.1Elected
Say on pay (advisory)110.84.20.896.3Approved
Ratify Ernst & Young for FY2026193.62.31.098.8Approved
Director votes show withheld in the against column. Broker non votes 81,112,511 on each item except the auditor ratification. Four of nine director elections shown; the other five received 114.3m to 114.6m votes for. Source: 8-K Item 5.07 of 2 Jun 2026.

Annual meeting

  • No meeting transcript or remarks were filed; the Item 5.07 8-K of 2 Jun 2026 reports only the vote results.
Table 9.2 Holders and voting power
HolderSourceSharesShare of class
Van Eck AssociatesSchedule 13G/A, 30 Sep 202628,046,4476.8% of Class A
BlackRockSchedule 13G, 30 Jun 202622,370,7146.5% of Class A
Vanguard Capital ManagementSchedule 13G, 30 Sep 202621,577,4485.25% of Class A
Japan NuScale Innovation (JGC, IHI, Chubu, JBIC)2026 proxy (30 Mar 2026)19,285,070 Class B5.71% of voting power
Directors and executive officers (13)2026 proxy (30 Mar 2026)4,159,7041.28% of Class A
FluorForms 4, Feb to Apr 20260exited
Class A and Class B outstanding, 30 Oct 202610-Q Q3 2026 cover410,568,229 and 19,332,018100%
Class A and Class B carry one vote each. The 2026 proxy listed Fluor at 12.09% and The Goldman Sachs Group at 7.55% of voting power at 30 Mar 2026; Fluor sold its remaining shares in Apr 2026.
Table 9.3 Fluor's exit from NuScale as filed
DateEventSource
7 Nov 2025Exchanged 110,936,472 NuScale LLC Class B units into Class A shares; TRA payments due to Fluor cut by 50%Schedule 13D/A no. 6, filed 10 Nov 2025
9 Nov 2025Letter agreement to sell 71,000,000 shares to Goldman Sachs International at a variable priceSchedule 13D/A no. 6
13 Feb 202671,000,000 shares sold to Goldman Sachs at $19.0498Form 4; Schedule 13D/A no. 7
17 Feb 2026Agreements to sell 13,500,000 + 13,500,000 shares to Bank of America and 12,936,472 to Citibank; 40,400,219 shares held after the GS sale (13.3%)Schedule 13D/A no. 7
26 Feb 2026463,747 shares sold at $13.1466Form 4
9 Apr 202613,500,000 shares sold at $12.0665Form 4
15 Apr 202612,936,472 shares sold at $11.6293Form 4
21 Apr 202613,500,000 shares sold at $11.8092Form 4
Shares sold total 111,400,219; proceeds of about $1.83bn are derived from the prices on the Forms 4.
Table 9.4 Insider sales by person, Forms 4 of 14 Nov 2025 to 15 Nov 2026 (excl. Fluor)
PersonShares soldValue ($m)
Robert Ramsey Hamady, CFO148,4501.95
Carl Fisher, COO90,2451.07
John Hopkins, CEO82,6671.01
Jose Reyes, CTO25,9510.32
Clayton Scott, CCO22,4780.28
Shinji Fujino, director20,0000.18
David Tonnel, CAO2,2900.03
No open market purchases. Sales total $4.82m, of which $2.06m under Rule 10b5‑1 plans ($1.44m by the CFO and $0.62m by the COO); the rest are mainly sales on RSU vesting. Prices ranged from $7.89 to $22.17.

10 Risk Factors

  • Item 1A of the FY2025 10-K holds 40 risk factors against 45 a year earlier (11,807 words against 12,195): 3 added (the PMA with ENTRA1, US trade policy and dividends), 8 removed (incl. the SDA approval factor after the NRC approval of May 2025) and 10 materially reworded. The Forms 10-Q for Q1 to Q3 2026 report no material changes.
Table 10.1 Risk factors and legal matters with filed figures
RiskDisclosure and change
No binding NPM contractInitial deployment depends on RoPower and a Fluor EPC contract, or on an ENTRA1 PPA with a third party plus an OEM agreement with NuScale; neither existed at 5 Nov 2026.
PMA cash outlays (new)MC1 cost $507.4m for 72 NPMs; MC2 (35%) falls due on a binding PPA and MC3 (50%) on an OEM agreement; this report derives about $1.18bn and $1.69bn for the same NPMs from the filed 15% share, amounts the filings do not state.
Dependence on ENTRA1ENTRA1 holds exclusive worldwide rights and decides in its sole discretion whether to buy from NuScale; the factor grew from 233 to 381 words.
Funding and dilutionClass A plus Class B shares rose from 337.9m at 31 Dec 2025 to 429.9m at 30 Sep 2026; authorized Class A doubled to 662m; a $750m ATM program is open.
LitigationTruedson class action (filed 18 Feb 2026, amended 10 Jul 2026; class period 3 Mar to 6 Nov 2025) alleges misleading statements on ENTRA1's experience, qualifications and capabilities and Section 20A claims against Fluor; motion to dismiss filed 25 Sep 2026, opposition due 16 Nov 2026; derivative suits of 24 Mar 2026 (stayed) and 28 Oct 2026; no loss estimate.
Supply base and tariffsIf firm supplier orders are delayed, NuScale may lose manufacturing slots; long lead components are manufactured overseas, so US tariffs on them would raise costs (new factor).
CompetitionCommercial SMRs operate in China and Russia; other designs hold NRC construction permits and are under construction (10-K FY2025).

How risk factors changed

  • Comparison: 10-K FY2025 filed 26 Feb 2026 acc 0001822966-26-000018 against 10-K FY2024 filed 3 Mar 2025 acc 0001822966-25-000024.
  • ENTRA1 appears in the headings of 2 factors in FY2025 against 1 a year earlier; the PMA factor is new.
  • The SDA approval factor was dropped after the NRC approval of May 2025.
  • Supply chain risk moved from raw material availability to supplier commitment and manufacturing slots.
Figure 10.1 Risk factors by change against the prior filing
Table 10.2 Size of the risk factor section
Measure10-K FY202410-K FY2025
Risk factors (count)4540
Words in Item 1A12,19511,807
Table 10.3 Risk factors added, removed and materially reworded
ChangeRisk factorWhat changed
AddedPMA with ENTRA1: cash outlays without revenueNew factor: Milestone Contribution 1 for 72 NPMs cost about $507m; MC2 is due on a binding PPA and MC3 on an OEM agreement; contributions are unrecoverable if ENTRA1 generates no projects.
AddedUS trade policy and tariffsNew factor: long lead components are made overseas, so tariffs on imports raise costs; retaliatory tariffs may hurt exports.
AddedNo cash dividends expectedNew factor: earnings retained to fund the business.
RemovedSDA applications may not be approvedRemoved after the NRC approved the 77 MWe SDA in May 2025.
RemovedMaterial weakness in internal controlRemoved; the FY2024 factor described an identified material weakness.
RemovedRaw material availability and costsIts tariff and trade content moved into the new US trade policy factor; supply content into the constrained supply base factor.
RemovedExercisable NuScale options and dilutionRemoved as a separate factor.
RemovedNYSE listing and trading limitsRemoved.
RemovedTax law changesRemoved as a separate factor.
RemovedChanging laws on governance and disclosureRemoved.
RemovedSecurities litigationMerged into the general litigation factor, which now names the class action on ENTRA1 statements.
RewordedReliance on ENTRA1, Fluor and partnersText grows from 233 to 381 words; ENTRA1 now listed first with exclusive worldwide rights under the Strategic Alliance Agreement of 7 May 2025, which restricts NuScale from contacting ENTRA1 relationships.
RewordedNo binding NPM contractInitial deployment now tied to RoPower and a Fluor EPC contract, or an ENTRA1 PPA with a third party and an OEM agreement with NuScale.
RewordedCompetition from other technologiesHeading broadened from China and Russia SMRs to all reactor technologies; adds that other designs hold NRC construction permits and are under construction.
RewordedConstrained supply baseRewritten: until a binding NPM contract exists, suppliers may give slots to others, gain pricing power or become less responsive.
RewordedNeed for additional fundingAdds that financing may not be available on acceptable terms and that equity raises dilute holders.
RewordedEvolving laws and regulationsText grows from 162 to 299 words; adds the 2024 Loper Bright decision ending Chevron deference.
RewordedManaging growthShortened from 173 to 77 words; refers to finding locations or partners to expand NPM manufacture.
RewordedLitigationNow names the class action in the District of Oregon on statements about ENTRA1 and states that a loss would be material.
RewordedPublic health crisesRewritten in general terms.
RewordedDelays in NPM developmentExpanded from 161 to 229 words.
Table 10.4 Risk factor updates in quarterly reports since the annual filing
FilingChange disclosed
10-Q Q1 2026 filed 7 May 2026No material changes from the FY2025 10-K.
10-Q Q2 2026 filed 5 Aug 2026No material changes from the FY2025 10-K.
10-Q Q3 2026 filed 5 Nov 2026No material changes from the FY2025 10-K.

11 Stock Price, Scenarios & Sensitivity

  • SMR closed at $4.66 on 13 Nov 2026, after closes of $5.13 on 4 Nov, $4.37 on 5 Nov (the Q3 2026 release date) and $5.08 on 6 Nov 2026. The close is 80% below the 52 week intraday high of $23.45 (14 Nov 2025) and 8.9% above the 52 week low of $4.28; it compares with $11.14, the average price of the H1 2026 ATM sales, and $19.0498, Fluor's sale price to Goldman Sachs in Feb 2026.
  • Market value $2.00bn on 429.9m Class A and Class B shares, counting each Class B share with its NuScale LLC unit as one Class A share since the pair is exchangeable for Class A (this report's basis; Class A alone $1.91bn); cash and investments $1.86bn and no debt, so enterprise value is $139m. P/E and EV/sales are left out, given TTM losses and TTM revenue of $2.7m.
  • Scenario basis (this report's assumptions, not company guidance): implied price equals TTM Q3 2029 revenue times an exit EV/sales multiple, plus net cash of $1.30bn, divided by the share count after new equity. Net cash is today's $1.86bn less three years of the 9M 2026 operating cash use excluding MC1, about $189m a year (derived). The model deducts no MC2 or MC3 contributions from net cash; in the best case they are assumed to be funded with new shares.
Figure 11.1 SMR monthly closing price and three year scenarios

Critical factors and core assumptions

Table 11.1 Critical factors behind the best case
FactorCurrent valueBest case requiresEvidence in filings
Binding PPA between ENTRA1 and TVAnon binding agreement for up to 6 GW (2 Sep 2025); no PPA at 5 Nov 2026PPA in 2027 and an OEM agreement for NPMs10-Q Q3 2026 MD&A and Note 9
Funding of MC2 and MC3about $1.18bn and $1.69bn for 72 NPMs (this report's derivation from the 15% share; not filed) against cash of $1.86bnpayments matched by NPM order proceeds and equity at higher prices10-Q Q3 2026 Note 9
First NPM fabricationDoosan contract for the upper reactor coolant system (Oct 2026); LLM $69.7mfirst module delivered on schedule and cost8-K Ex 99.1, 5 Nov 2026; 10-Q Note 7
RoPower financingRomanian investment decision approved 12 Feb 2026; pre EPC contract awaits financingpre EPC contract and long lead orders in 202710-Q Q3 2026 MD&A
Cash use9M 2026 operating cash use $141.5m excl. MC1 (derived); investment income $19.1m in Q3 2026cash use held near $189m a year8-K Ex 99.1 cash flow statements
Litigation over ENTRA1 statementsclass action and two derivative suits pendingdismissal without material loss10-Q Q3 2026 Note 13
  • Revenue path (report assumption): TTM Q3 2029 revenue of $1.50bn (best), $250m (base) and $10m (worst) from TTM Q3 2026 revenue of $2.7m; the CAGRs follow from these levels. NuScale gives no revenue guidance.
  • Best case (report assumption): ENTRA1 signs a TVA PPA and an OEM agreement, NPM deliveries begin and RoPower moves to pre EPC; exit 4x EV/sales, near BWXT at 3.5x and GE Vernova at 4.5x; 50% more shares to fund MC2 and MC3; implied price $11.32, +143% against the close.
  • Base case (report assumption): a PPA arrives late in the period with first engineering and NPM revenue; exit 5x EV/sales; 20% more shares (about 86m shares, or about $400m at the 13 Nov 2026 close, against the open $750m ATM program); implied price $4.94, +6% against the close.
  • Worst case (report assumption): no PPA or OEM agreement, revenue stays at E2 Center and service levels; exit 3x EV/sales; 10% more shares; implied price $2.81, (40%) against the close, mostly remaining cash.
  • Share count 429.9m Class A and Class B at 30 Oct 2026. Operating margins are not used in the EV/sales model. NuScale pays no dividend.

Scenarios, three years forward

Table 11.2 Scenario analysis, TTM Q3 2026 revenue of $2.7m to TTM Q3 2029
MeasureWorst caseBase caseBest case
Revenue CAGR, 3 years (%)54.2350.8719.1
Revenue, TTM Q3 2029 ($bn)0.00.31.5
Exit EV/Sales (x)3.05.04.0
Implied price ($)2.814.9411.32
Change against $4.66 (%)(40)6143
Implied annual return (%)(15.5)2.034.4
DescriptionNo PPA, cash runs downLate PPA, first NPM revenueTVA PPA and OEM agreement signed
Valuation basis (this report's assumptions): no MC2 or MC3 outflow is deducted; exit EV/sales on TTM Q3 2029 revenue plus net cash of $1.30bn (today's cash less three years of burn at the 9M 2026 rate excluding MC1); share count 429.9m plus 50% (best), 20% (base) or 10% (worst). Worst case revenue of $10m shows as 0.0 in $bn.
Figure 11.2 Three year price scenarios

Sensitivity analysis

Table 11.3 Sensitivity of implied price to revenue CAGR and exit EV/Sales
Revenue CAGR \ EV/Sales2x3x5x8x
100%$2.60$2.64$2.73$2.85
200%$2.80$2.94$3.23$3.66
350%$3.48$3.96$4.93$6.37
500%$4.80$5.94$8.23$11.66
720%$8.35$11.27$17.10$25.85
Cells show implied share price in year 3. Close of 13 Nov 2026 $4.66. Blue cells sit above it, red cells below. Revenue CAGR from TTM Q3 2026 revenue of $2.7m: 100% gives $21.8m in year 3, 200% $73.7m, 350% $249m, 500% $589m, 720% $1.50bn. Each cell uses net cash of $1.30bn and 515.9m shares (base case).

Disclaimer

This analysis is for information only and is not financial advice. It is derived from public SEC filings retrieved via sec-api.io and is not a publication of the U.S. Securities and Exchange Commission. Scenario values are model outputs under stated assumptions and are not forecasts. Data as of 15 Nov 2026, with filings to 13 Nov 2026 and the share price at the 13 Nov 2026 close.

Sources

All company and peer figures are read from SEC filings retrieved through the sec-api.io MCP server. Share prices are regular session closes as dated in the text.

Table A.1 Filings used, with accession numbers
FormPeriodFiledAccession number
8-K Ex 99.1 (Q3 2026 results)30 Sep 20265 Nov 20260001822966-26-000089
10-Q Q3 202630 Sep 20265 Nov 20260001822966-26-000091
10-Q Q2 202630 Jun 20265 Aug 20260001822966-26-000085
10-Q Q1 202631 Mar 20267 May 20260001822966-26-000054
10-K FY202531 Dec 202526 Feb 20260001822966-26-000018
10-K FY202431 Dec 20243 Mar 20250001822966-25-000024
10-K FY202331 Dec 202315 Mar 20240001822966-24-000039
10-K FY202231 Dec 202215 Mar 20230001822966-23-000059
10-Q Q3 202530 Sep 20256 Nov 20250001822966-25-000175
10-Q Q2 202530 Jun 20257 Aug 20250001822966-25-000133
10-Q Q1 202531 Mar 202512 May 20250001822966-25-000088
DEF 14A 202615 Apr 202615 Apr 20260001822966-26-000042
SC 13D/A no. 7 (Fluor)13 Feb 202617 Feb 20260001124198-26-000015
SC 13D/A no. 6 (Fluor)6 Nov 202510 Nov 20250001124198-25-000094
Schedule 13G/A (Van Eck)30 Sep 202613 Nov 20260000869178-26-000111
Schedule 13G (Vanguard Capital Management)30 Sep 202630 Oct 20260002100119-26-001663
Schedule 13G (BlackRock)30 Jun 202629 Jul 20260002012383-26-002835
Form 4 (Fluor, 13.5m shares)21 Apr 202623 Apr 20260001124198-26-000049
Form 4 (Fluor, 71.0m shares)13 Feb 202617 Feb 20260001124198-26-000016
Table A.2 Forms 8-K and peer filings used
CompanyFormFiledAccession number
NuScale Power8-K (Items 5.02, 5.03, 8.01)17 Nov 20250001822966-25-000179
NuScale Power8-K (Items 5.03, 5.07)17 Dec 20250001822966-25-000186
NuScale Power8-K (Items 7.01)27 Jan 20260001822966-26-000007
NuScale Power8-K (Items 2.02)26 Feb 20260001822966-26-000016
NuScale Power8-K (Items 1.01, 1.02)26 Feb 20260001822966-26-000019
NuScale Power8-K (Items 7.01)8 Apr 20260001822966-26-000038
NuScale Power8-K (Items 2.02)7 May 20260001822966-26-000052
NuScale Power8-K (Items 5.07)2 Jun 20260001822966-26-000058
NuScale Power8-K (Items 2.02)5 Aug 20260001822966-26-000086
NuScale Power8-K (Items 1.01)11 Aug 20260001104659-26-094073
NuScale Power8-K (Items 2.02)5 Nov 20260001822966-26-000089
BWX Technologies10-K FY202523 Feb 20260001486957-26-000007
BWX Technologies10-Q Q3 20262 Nov 20260001486957-26-000051
GE Vernova10-K FY202529 Jan 20260001996810-26-000015
GE Vernova10-Q Q3 202628 Oct 20260001996810-26-000163
NANO Nuclear Energy10-K FY2025 (Sep 2025)18 Dec 20250001493152-25-028285
NANO Nuclear Energy10-Q Jun 2026 quarter12 Aug 20260001493152-26-037345
Oklo10-K FY202517 Mar 20260001628280-26-018698
Oklo10-Q Q3 20266 Nov 20260001628280-26-071319
Table B.1 Exhibits to Forms 8-K filed in the last twelve months
FiledExhibitDocumentContent
17 Nov 2025Ex 3.1Amended and Restated BylawsArticle V names the Chief Accounting Officer as an officer; Controller no longer required to be the Chief Accounting Officer.
17 Nov 2025Ex 10.1Deferred Compensation Plan for Non Employee Directors (22 Nov 2025)Directors may defer cash retainers paid in Class A shares and RSU awards; Deferral runs to separation from service, change in control, death or disability.
17 Dec 2025Ex 3.1Certificate of AmendmentAuthorized Class A shares raised from 332,000,000 to 662,000,000; Approved by 184.5m votes for and 28.0m against on 16 Dec 2025.
27 Jan 2026Ex 99.1Call announcement, Q4 and FY2025Results call set for 26 Feb 2026 at 5:00 pm ET.
26 Feb 2026Ex 99.1Q4 and FY2025 results releaseFY2025 revenue $31.5m against $37.0m; cost of sales $20.0m against $4.9m; G&A $609.8m incl. Milestone Contribution 1 of $507.4m; cash and investments $1.3bn; 39.3m ATM shares for $750.0m gross in Q4 2025.
26 Feb 2026Ex 1.1Sales Agreement, $1.0bn ATM programAgents UBS, B. Riley, Canaccord and Tuohy Brothers; commission up to 2%; Program completed in Jun 2026: 89.7m shares for $1.0bn gross (10-Q).
26 Feb 2026Ex 5.1Legal opinion (O'Melveny & Myers)Validity of shares issued under the Sales Agreement.
26 Feb 2026Ex 23.1Consent of counselConsent to the opinion filed as Ex 5.1.
8 Apr 2026Ex 99.1Call announcement, Q1 2026Results call set for 7 May 2026 at 5:00 pm ET.
7 May 2026Ex 99.1Q1 2026 results releaseRevenue $0.6m against $13.4m; net loss $46.7m; liquidity $1.0bn; Nuclearelectrica shareholders approved the next RoPower phase; Framatome partnership expanded.
5 Aug 2026Ex 99.1Q2 2026 results releaseRevenue $0.1m against $8.1m; R&D +$6.6m; liquidity $1.9bn; Paragon contract for the HIPS final design; supply chain of over 60 partners and over 30 agreements.
11 Aug 2026Ex 1.1Sales Agreement, $750m ATM programAgents UBS, B. Riley, Canaccord, Craig‑Hallum, Texas Capital Securities and Tuohy Brothers; commission up to 2%; No shares sold in Q3 2026 (10-Q).
11 Aug 2026Ex 5.1Legal opinion (O'Melveny & Myers)Validity of shares issued under the Sales Agreement.
5 Nov 2026Ex 99.1Q3 2026 results releaseRevenue $0.3m against $8.2m; G&A down $491.3m; investment income $19.1m (+$13.4m); Doosan contract for the upper reactor coolant system; cash and investments $1.9bn.